Authors : Deepika A.; Ariharasivakumar G.

Volume/Issue : Volume 11 - 2026, Issue 8 - August

Google Scholar : https://tinyurl.com/5n8xbxf4

Scribd : https://tinyurl.com/jzksaxbt

DOI : https://doi.org/10.38124/ijisrt/26aug244

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Margetuximab is a new chimeric IgG1 monoclonal antibody designed to enhance antitumor activity in the immune system and treat patients with HER2-positive malignant disease. Margetuximab selectively binds to activate the Fcγ receptor CD16A and shows reduced binding to inhibitory Fcγ receptor CD32B, thereby enhancing antibody-dependent cellular cytotoxicity (ADCC) and providing greater therapeutic potential than conventional HER2-targeted antibodies. This review covers the discovery, physicochemical properties, pharmacokinetic properties, mechanism of action, synthesis, and clinical applications of margetuximab. Furthermore, this review covers evidence of its efficacy, safety profile, adverse effects, drug interactions, contraindications, conventional formulations, emerging formulations, and patents. The efficacy of margetuximab in combination with chemotherapy in clinical studies suggests it is a useful treatment option in the metastatic setting for patients with HER2-positive breast cancer who have failed previous anti-HER2 treatment, have a manageable toxicity profile, and have improved immune-mediated antitumor responses. Moreover, continuous clinical research and formulation strategy development are ongoing to further advance its therapeutic applications. Overall, margetuximab represents a significant improvement in HER2-targeted therapy, and further studies are likely to enhance its clinical effectiveness and expand its potential applications in precision oncology.

Keywords : Margetuximab, HER2-Positive Breast Cancer, Fc-Engineered Antibody, Antibody-Dependent Cellular Cytotoxicity (ADCC), Pharmacokinetics, Clinical Applications, Targeted Therapy, Monoclonal Antibody, Immunotherapy, Metastatic Breast Cancer.

References :

1. Dormann C. Metastatic human epidermal growth factor receptor 2-positive breast cancer: current treatment standards and future perspectives. Breast Care. 2020 Dec 7;15(6):570-8.
2.  Schlam I, Nunes R, Lynce F. Profile of Margetuximab: evidence to date in the targeted treatment of metastatic HER2-positive breast cancer. OncoTargets and Therapy. 2022 Apr 28:471-8.
3.  Markham A. Margetuximab: first approval. Drugs. 2021 Apr;81(5):599-604.
4. Tarantino P, Morganti S, Uliano J, Giugliano F, Crimini E, Curigliano G. Margetuximab for the treatment of HER2-positive metastatic breast cancer. Expert Opinion on Biological Therapy. 2021 Feb 1;21(2):127-33.
5. Khakinahad Y, Sohrabi S, Razi S, Narmani A, Khaleghi S, Asadiyun M, Jafari H, Mohammadnejad J. Margetuximab conjugated-PEG-PAMAM G4 nano-complex: a smart nano-device for suppression of breast cancer. Biomedical Engineering Letters. 2022 Aug;12(3):317-29.
6. Narmani A, Mohammadnejad J, Yavari K. Synthesis and evaluation of polyethene glycol-and folic acid-conjugated polyamidoamine G4 dendrimer as nanocarrier. Journal of Drug Delivery Science and Technology. 2019 Apr 1;50:278-86.
7. Chang Y, Liu N, Chen L, Meng X, Liu Y, Li Y, Wang J. Synthesis and characterisation of DOX-conjugated dendrimer-modified magnetic iron oxide conjugates for magnetic resonance imaging, targeting, and drug delivery. Journal of Materials Chemistry. 2012 Jan 1;22(19):9594.
8.  Narmani A, Arani MA, Mohammadnejad J, Vaziri AZ, Solymani S, Yavari K, Talebi F, Darzi SJ. Breast tumour targeting with PAMAM-PEG-5FU-99mTc as a new therapeutic nanocomplex: in vitro and in vivo studies. Biomedical microdevices. 2020 Jun;22(2):31.
9. Hsu CH, Chen SK, Chen WY, Tsai ML, Chen RH. Effect of the characters of chitosans used and regeneration conditions on the yield and physicochemical characteristics of regenerated products. International journal of molecular sciences. 2015 Apr 17;16(4):8621-34.
10. Narmani A, Kamali M, Amini B, Salimi A, Panahi Y. Targeting delivery of oxaliplatin with smart PEG-modified PAMAM G4 to colorectal cell line: In vitro studies. Process Biochemistry. 2018 Jun 1;69:178-87.
11. Mekuria SL, Tsai HC. Preparation of self-assembled core–shell nano structure of conjugated generation 4.5 poly (amidoamine) dendrimer and monoclonal Anti-IL-6 antibody as bioimaging probe. Colloids and Surfaces B: Biointerfaces. 2015 Nov 1; 135:253-60.
12. Bang YJ, Giaccone G, Im SA, Oh DY, Bauer TM, Nordstrom JL, Li H, Chichili GR, Moore PA, Hong S, Stewart SJ. First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumours. Annals of Oncology. 2017 Apr 1;28(4):855-61.
13. Alasmari MM. A review of margetuximab-based therapies in patients with HER2-positive metastatic breast cancer. Cancers. 2022 Dec 21;15(1):38.
14. Musolino A, Gradishar WJ, Rugo HS, Nordstrom JL, Rock EP, Arnaldez F, Pegram MD. Role of Fcγ receptors in HER2-targeted breast cancer therapy. Journal for immunotherapy of cancer. 2022 Jan 6;10(1):e003171.
15. Melanie Royce, Christy L. Osgood, Anup K. Amatya, Mallorie H. Fiero, C.J. George Chang, et al. Margetuximab plus chemotherapy for advanced or metastatic HER2-positive breast cancer. HHS Public Access.2022; 28(8). Pg No:1487-1492.
16. Theodore R, Harvey WW.30 June 1906 https://www.margenza.com/pdf/prescribing-information.pdf
17. Melanie R. 15 April 2022. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-margetuximab-metastatic-her2-positive-breast-cancer
18. Cuellar,Sandra.Expert commentary on the product profile of Margetuximab for HER2-Positive breast cancer. Oncology.01 Sep 2021.
19. Prescriber’s Digital Reference . https://www.pdr.net/drug-summary/Idamycin-PFS-idarubicin-hydrochloride-1018
20. Government regulations. https://www.regulations.gov/docket/FDA-2021-E-0450/document.